{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:29:17Z","timestamp":1793716157193,"version":"4.6.1"},"reference-count":297,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41571-025-01061-7","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:14:37Z","timestamp":1755184477000},"page":"806-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Treatment of NSCLC after chemoimmunotherapy \u2014 are we making headway?"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-4462","authenticated-orcid":false,"given":"Martin","family":"Reck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-7129","authenticated-orcid":false,"given":"Nikolaj","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1538-2091","authenticated-orcid":false,"given":"Rajkumar","family":"Savai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5793-3539","authenticated-orcid":false,"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359\u2013E386 (2015).","journal-title":"Int. J. Cancer"},{"key":"1061_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader, N. et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 383, 640\u2013649 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang, M., Herbst, R. S. & Boshoff, C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat. Med. 27, 1345\u20131356 (2021).","journal-title":"Nat. Med."},{"key":"1061_CR4","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u226550. J. Clin. Oncol. 39, 2339\u20132349 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR5","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino, M. C. et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J. Clin. Oncol. 41, 1992\u20131998 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello, S. et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J. Clin. Oncol. 41, 1999\u20132006 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer, J. R. et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J. Clin. Oncol. 41, 1200\u20131212 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR8","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.jtho.2023.09.076","volume":"18","author":"SS Ramalingam","year":"2023","unstructured":"Ramalingam, S. S. et al. Six-year survival and HRQoL outcomes with 1L nivolumab + ipilimumab in patients with metastatic NSCLC from CheckMate227 [abstract OA14.03]. J. Thorac. Oncol. 18, S76\u2013S77 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR9","doi-asserted-by":"publisher","first-page":"114296","DOI":"10.1016\/j.ejca.2024.114296","volume":"211","author":"M Reck","year":"2024","unstructured":"Reck, M. et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur. J. Cancer 211, 114296 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1061_CR10","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR11","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst, R. S. et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N. Engl. J. Med. 383, 1328\u20131339 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer, A. et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 397, 592\u2013604 (2021).","journal-title":"Lancet"},{"key":"1061_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMc2032432","volume":"384","author":"N Horita","year":"2021","unstructured":"Horita, N., Fukuda, N. & Kaneko, T. Atezolizumab for PD-L1-selected patients with NSCLC. N. Engl. J. Med. 384, 583\u2013584 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR14","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"1061_CR15","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR16","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924\u2013937 (2019).","journal-title":"Lancet Oncol."},{"key":"1061_CR18","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040\u20132051 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares, L. et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J. Thorac. Oncol. 15, 1657\u20131669 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR20","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"M Gogishvili","year":"2022","unstructured":"Gogishvili, M. et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat. Med. 28, 2374\u20132380 (2022).","journal-title":"Nat. Med."},{"key":"1061_CR21","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares, L. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 198\u2013211 (2021).","journal-title":"Lancet Oncol."},{"key":"1061_CR23","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson, M. L. et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J. Clin. Oncol. 41, 1213\u20131227 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","volume":"17","author":"LG Paz-Ares","year":"2022","unstructured":"Paz-Ares, L. G. et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J. Thorac. Oncol. 17, 289\u2013308 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","volume":"635","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis, F. et al. CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors. Nature 635, 462\u2013471 (2024).","journal-title":"Nature"},{"key":"1061_CR26","doi-asserted-by":"publisher","first-page":"1146905","DOI":"10.3389\/fonc.2023.1146905","volume":"13","author":"M Alifu","year":"2023","unstructured":"Alifu, M. et al. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis. Front. Oncol. 13, 1146905 (2023).","journal-title":"Front. Oncol."},{"key":"1061_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir. Med. 9, 305\u2013314 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1061_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL phase 3 trial. J. Thorac. Oncol. 18, 628\u2013639 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","volume":"17","author":"S Ren","year":"2022","unstructured":"Ren, S. et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial. J. Thorac. Oncol. 17, 544\u2013557 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR30","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J. Thorac. Oncol. 15, 1636\u20131646 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","volume":"171","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Final overall survival data of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. Lung Cancer 171, 56\u201360 (2022).","journal-title":"Lung Cancer"},{"key":"1061_CR32","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J. Thorac. Oncol. 16, 1501\u20131511 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR33","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","volume":"16","author":"S Lu","year":"2021","unstructured":"Lu, S. et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J. Thorac. Oncol. 16, 1512\u20131522 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 7, 709\u2013717 (2021).","journal-title":"JAMA Oncol."},{"key":"1061_CR35","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","volume":"30","author":"EJ Aguilar","year":"2019","unstructured":"Aguilar, E. J. et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann. Oncol. 30, 1653\u20131659 (2019).","journal-title":"Ann. Oncol."},{"key":"1061_CR36","first-page":"100675","volume":"5","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti, B. et al. Three-year overall survival outcomes and correlative analyses in patients with NSCLC and high (50%-89%) versus very high (\u226590%) programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab. JTO Clin. Res. Rep. 5, 100675 (2024).","journal-title":"JTO Clin. Res. Rep."},{"key":"1061_CR37","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","volume":"24","author":"M Ozguroglu","year":"2023","unstructured":"Ozguroglu, M. et al. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 24, 989\u20131001 (2023).","journal-title":"Lancet Oncol."},{"key":"1061_CR38","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd, F. A. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095\u20132103 (2000).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck, M. et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15, 143\u2013155 (2014).","journal-title":"Lancet Oncol."},{"key":"1061_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665\u2013673 (2014).","journal-title":"Lancet"},{"key":"1061_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","volume":"55","author":"A Ravi","year":"2023","unstructured":"Ravi, A. et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat. Genet. 55, 807\u2013819 (2023).","journal-title":"Nat. Genet."},{"key":"1061_CR42","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.23.00580","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti, B. et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer. J. Clin. Oncol. 42, 1311\u20131321 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR43","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.annonc.2024.06.014","volume":"35","author":"A Di Federico","year":"2024","unstructured":"Di Federico, A. et al. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Ann. Oncol. 35, 902\u2013913 (2024).","journal-title":"Ann. Oncol."},{"key":"1061_CR44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10555-023-10144-9","volume":"43","author":"H Fatma","year":"2024","unstructured":"Fatma, H. & Siddique, H. R. Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked? Cancer Metastasis Rev. 43, 423\u2013440 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"1061_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","volume":"16","author":"AR Delbridge","year":"2016","unstructured":"Delbridge, A. R. et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer 16, 99\u2013109 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"1061_CR46","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","volume":"5","author":"AN Hata","year":"2015","unstructured":"Hata, A. N., Engelman, J. A. & Faber, A. C. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 5, 475\u2013487 (2015).","journal-title":"Cancer Discov."},{"key":"1061_CR47","doi-asserted-by":"publisher","first-page":"101821","DOI":"10.1016\/j.tranon.2023.101821","volume":"39","author":"HQ Sadida","year":"2024","unstructured":"Sadida, H. Q. et al. Epigenetic modifications: key players in cancer heterogeneity and drug resistance. Transl. Oncol. 39, 101821 (2024).","journal-title":"Transl. Oncol."},{"key":"1061_CR48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","volume":"8","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal. Transduct. Target. Ther. 8, 210 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1061_CR49","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger, S. et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 7, 1420\u20131435 (2017).","journal-title":"Cancer Discov."},{"key":"1061_CR50","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin. Cancer Res. 26, 487\u2013504 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1061_CR52","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249\u2013253 (2015).","journal-title":"Nature"},{"key":"1061_CR53","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1038\/s41388-018-0125-3","volume":"37","author":"Q Lai","year":"2018","unstructured":"Lai, Q. et al. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN\/PD-L1 signal of lung cancer cells. Oncogene 37, 2302\u20132312 (2018).","journal-title":"Oncogene"},{"key":"1061_CR54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J. Immunother. Cancer 7, 305 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008028","volume":"12","author":"GD Guler","year":"2024","unstructured":"Guler, G. D. et al. Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer. J. Immunother. Cancer 12, e008028 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR56","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s12276-023-01014-z","volume":"55","author":"ML Jin","year":"2023","unstructured":"Jin, M. L. & Jeong, K. W. Histone modifications in drug-resistant cancers: from a cancer stem cell and immune evasion perspective. Exp. Mol. Med. 55, 1333\u20131347 (2023).","journal-title":"Exp. Mol. Med."},{"key":"1061_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.acr.2022.12.001","volume":"158","author":"RR Walker","year":"2023","unstructured":"Walker, R. R., Rentia, Z. & Chiappinelli, K. B. Epigenetically programmed resistance to chemo- and immuno-therapies. Adv. Cancer Res. 158, 41\u201371 (2023).","journal-title":"Adv. Cancer Res."},{"key":"1061_CR58","doi-asserted-by":"publisher","first-page":"eade4656","DOI":"10.1126\/sciimmunol.ade4656","volume":"8","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Sci. Immunol. 8, eade4656 (2023).","journal-title":"Sci. Immunol."},{"key":"1061_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01260-z","volume":"19","author":"L Horvath","year":"2020","unstructured":"Horvath, L. et al. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) \u2014 novel approaches and future outlook. Mol. Cancer 19, 141 (2020).","journal-title":"Mol. Cancer"},{"key":"1061_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49282-1","volume":"15","author":"A Varveri","year":"2024","unstructured":"Varveri, A. et al. Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumour development. Nat. Commun. 15, 4988 (2024).","journal-title":"Nat. Commun."},{"key":"1061_CR61","doi-asserted-by":"publisher","first-page":"eaax7918","DOI":"10.1126\/scitranslmed.aax7918","volume":"11","author":"N McGranahan","year":"2019","unstructured":"McGranahan, N. & Swanton, C. Neoantigen quality, not quantity. Sci. Transl. Med. 11, eaax7918 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1061_CR62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41416-024-02698-4","volume":"131","author":"H Jeong","year":"2024","unstructured":"Jeong, H. et al. Epithelial\u2212mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. Br. J. Cancer 131, 23\u201336 (2024).","journal-title":"Br. J. Cancer"},{"key":"1061_CR63","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.trecan.2020.02.001","volume":"6","author":"LA Horn","year":"2020","unstructured":"Horn, L. A., Fousek, K. & Palena, C. Tumor plasticity and resistance to immunotherapy. Trends Cancer 6, 432\u2013441 (2020).","journal-title":"Trends Cancer"},{"key":"1061_CR64","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"key":"1061_CR65","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015).","journal-title":"Nature"},{"key":"1061_CR66","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3892\/ijo.2024.5684","volume":"65","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Drug resistance and tumor immune microenvironment: an overview of current understandings (review). Int. J. Oncol. 65, 96 (2024).","journal-title":"Int. J. Oncol."},{"key":"1061_CR67","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13046-022-02524-w","volume":"41","author":"S Rizzolio","year":"2022","unstructured":"Rizzolio, S., Giordano, S. & Corso, S. The importance of being CAFs (in cancer resistance to targeted therapies). J. Exp. Clin. Cancer Res. 41, 319 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1061_CR68","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang, D. et al. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp. Mol. Med. 55, 1322\u20131332 (2023).","journal-title":"Exp. Mol. Med."},{"key":"1061_CR69","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.xcrm.2025.102017","volume":"6","author":"Z Cao","year":"2025","unstructured":"Cao, Z. et al. Interferon-\u03b3-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer. Cell Rep. Med. 6, 102017 (2025).","journal-title":"Cell Rep. Med."},{"key":"1061_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","volume":"120","author":"NA Giraldo","year":"2019","unstructured":"Giraldo, N. A. et al. The clinical role of the TME in solid cancer. Br. J. Cancer 120, 45\u201353 (2019).","journal-title":"Br. J. Cancer"},{"key":"1061_CR71","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides, A. et al. The complex role of tumor-infiltrating macrophages. Nat. Immunol. 23, 1148\u20131156 (2022).","journal-title":"Nat. Immunol."},{"key":"1061_CR72","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","volume":"119","author":"DA Hume","year":"2012","unstructured":"Hume, D. A. & MacDonald, K. P. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119, 1810\u20131820 (2012).","journal-title":"Blood"},{"key":"1061_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2025.02.004","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Targeting tumor-associated neutrophils: a promising strategy in lung cancer immunotherapy. Cancer Pathog. Ther., https:\/\/doi.org\/10.1016\/j.cpt.2025.02.004 (2025).","journal-title":"Cancer Pathog. Ther."},{"key":"1061_CR74","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-\u03b2: \u201cN1\u201d versus \u201cN2\u201d TAN. Cancer Cell 16, 183\u2013194 (2009).","journal-title":"Cancer Cell"},{"key":"1061_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002875","volume":"9","author":"Y Chenghui","year":"2021","unstructured":"Chenghui, Y. et al. Aged neutrophils form mitochondria-dependent vital NETs to promote breast cancer lung metastasis. J. Immunother. Cancer 9, e002875 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR76","doi-asserted-by":"publisher","first-page":"867516","DOI":"10.3389\/fimmu.2022.867516","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Neutrophil extracellular traps (NETs) promote non-small cell lung cancer metastasis by suppressing lncRNA MIR503HG to activate the NF-\u03baB\/NLRP3 inflammasome pathway. Front. Immunol. 13, 867516 (2022).","journal-title":"Front. Immunol."},{"key":"1061_CR77","doi-asserted-by":"publisher","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","volume":"177","author":"AG Jarnicki","year":"2006","unstructured":"Jarnicki, A. G. et al. Suppression of antitumor immunity by IL-10 and TGF-\u03b2-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 177, 896\u2013904 (2006).","journal-title":"J. Immunol."},{"key":"1061_CR78","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","volume":"21","author":"S Kumagai","year":"2024","unstructured":"Kumagai, S., Itahashi, K. & Nishikawa, H. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nat. Rev. Clin. Oncol. 21, 337\u2013353 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1061_CR79","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jtho.2023.12.015","volume":"19","author":"P Bischoff","year":"2024","unstructured":"Bischoff, P. et al. Outcome of first-line treatment with pembrolizumab according to KRAS\/TP53 mutational status for nonsquamous programmed death-ligand 1-high (\u226550%) NSCLC in the German National Network Genomic Medicine Lung Cancer. J. Thorac. Oncol. 19, 803\u2013817 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40745-5","volume":"14","author":"S Hiltbrunner","year":"2023","unstructured":"Hiltbrunner, S. et al. Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype. Nat. Commun. 14, 5154 (2023).","journal-title":"Nat. Commun."},{"key":"1061_CR81","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash, J. & Shaked, Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 14, 1375\u20131388 (2024).","journal-title":"Cancer Discov."},{"key":"1061_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei, L. et al. Roles of cancer-associated fibroblasts (CAFs) in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol. Cancer 22, 29 (2023).","journal-title":"Mol. Cancer"},{"key":"1061_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis. Oncol. 8, 31 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"1061_CR84","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang, B. et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J. Exp. Clin. Cancer Res. 40, 24 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1061_CR85","doi-asserted-by":"publisher","first-page":"100146","DOI":"10.1016\/j.cellin.2024.100146","volume":"3","author":"R Liu","year":"2024","unstructured":"Liu, R., Li, H. F. & Li, S. PD-1-mediated inhibition of T cell activation: mechanisms and strategies for cancer combination immunotherapy. Cell Insight 3, 100146 (2024).","journal-title":"Cell Insight"},{"key":"1061_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang, X. et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol. Cancer 18, 10 (2019).","journal-title":"Mol. Cancer"},{"key":"1061_CR87","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor, J. F. et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin. Cancer Res. 22, 4585\u20134593 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1061_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356145","volume":"6","author":"Z-Y Dong","year":"2017","unstructured":"Dong, Z.-Y. et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. OncoImmunology 6, e1356145 (2017).","journal-title":"OncoImmunology"},{"key":"1061_CR89","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jtho.2021.04.003","volume":"16","author":"M Qiao","year":"2021","unstructured":"Qiao, M. et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn? J. Thorac. Oncol. 16, 1267\u20131288 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR90","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","volume":"17","author":"N Nogami","year":"2022","unstructured":"Nogami, N. et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J. Thorac. Oncol. 17, 309\u2013323 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR91","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jtho.2023.02.009","volume":"18","author":"J Naidoo","year":"2023","unstructured":"Naidoo, J. et al. Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC. J. Thorac. Oncol. 18, 657\u2013663 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR92","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.23.02747","volume":"42","author":"JC Yang","year":"2024","unstructured":"Yang, J. C. et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J. Clin. Oncol. 42, 4029\u20134039 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR93","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis, F. et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822\u2013835 (2018).","journal-title":"Cancer Discov."},{"key":"1061_CR94","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","volume":"17","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J. Thorac. Oncol. 17, 399\u2013410 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR95","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","volume":"5","author":"F Skoulidis","year":"2015","unstructured":"Skoulidis, F. et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5, 860\u2013877 (2015).","journal-title":"Cancer Discov."},{"key":"1061_CR96","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3892\/ol.2021.12464","volume":"21","author":"S Muto","year":"2021","unstructured":"Muto, S. et al. Tumor \u03b2-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden. Oncol. Lett. 21, 203 (2021).","journal-title":"Oncol. Lett."},{"key":"1061_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09370-z","volume":"10","author":"D Kerdidani","year":"2019","unstructured":"Kerdidani, D. et al. Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma. Nat. Commun. 10, 1405 (2019).","journal-title":"Nat. Commun."},{"key":"1061_CR98","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon, D. et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell 42, 209\u2013224 e9 (2024).","journal-title":"Cancer Cell"},{"key":"1061_CR99","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"1061_CR100","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","volume":"187","author":"L Derosa","year":"2024","unstructured":"Derosa, L. et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell 187, 3373\u20133389.e16 (2024).","journal-title":"Cell"},{"key":"1061_CR101","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"1061_CR102","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"1061_CR103","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41564-020-00831-6","volume":"6","author":"SH Lee","year":"2021","unstructured":"Lee, S. H. et al. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat. Microbiol. 6, 277\u2013288 (2021).","journal-title":"Nat. Microbiol."},{"key":"1061_CR104","doi-asserted-by":"publisher","first-page":"2276314","DOI":"10.1080\/19490976.2023.2276314","volume":"15","author":"D Zhou","year":"2023","unstructured":"Zhou, D. & Li, Y. Gut microbiota and tumor-associated macrophages: potential in tumor diagnosis and treatment. Gut Microbes 15, 2276314 (2023).","journal-title":"Gut Microbes"},{"key":"1061_CR105","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1200\/JCO.22.00074","volume":"41","author":"L Eng","year":"2023","unstructured":"Eng, L. et al. Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study. J. Clin. Oncol. 41, 3122\u20133134 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR106","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.trre.2018.07.001","volume":"32","author":"SA Acuna","year":"2018","unstructured":"Acuna, S. A. Etiology of increased cancer incidence after solid organ transplantation. Transplant. Rev. 32, 218\u2013224 (2018).","journal-title":"Transplant. Rev."},{"key":"1061_CR107","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.3390\/cancers15082276","volume":"15","author":"J Colard-Thomas","year":"2023","unstructured":"Colard-Thomas, J., Thomas, Q. D. & Viala, M. Comedications with immune checkpoint inhibitors: involvement of the microbiota, impact on efficacy and practical implications. Cancers 15, 2276 (2023).","journal-title":"Cancers"},{"key":"1061_CR108","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann. Oncol. 31, 525\u2013531 (2020).","journal-title":"Ann. Oncol."},{"key":"1061_CR109","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/jnci\/djae295","volume":"117","author":"RJ Smith Jr","year":"2025","unstructured":"Smith, R. J. Jr et al. Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin. J. Natl Cancer Inst. 117, 673\u2013684 (2025).","journal-title":"J. Natl Cancer Inst."},{"key":"1061_CR110","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.trecan.2019.12.007","volume":"6","author":"AG Ramirez-Labrada","year":"2020","unstructured":"Ramirez-Labrada, A. G. et al. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy. Trends Cancer 6, 86\u201397 (2020).","journal-title":"Trends Cancer"},{"key":"1061_CR111","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nm.3568","volume":"20","author":"ES Gollwitzer","year":"2014","unstructured":"Gollwitzer, E. S. et al. Lung microbiota promotes tolerance to allergens in neonates via PD-L1. Nat. Med. 20, 642\u2013647 (2014).","journal-title":"Nat. Med."},{"key":"1061_CR112","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1508749","volume":"375","author":"MM Stein","year":"2016","unstructured":"Stein, M. M. et al. Innate immunity and asthma risk in Amish and Hutterite farm children. N. Engl. J. Med. 375, 411\u2013421 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR113","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1126\/science.1219328","volume":"336","author":"T Olszak","year":"2012","unstructured":"Olszak, T. et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336, 489\u2013493 (2012).","journal-title":"Science"},{"key":"1061_CR114","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/2326-6066.CIR-15-0062","volume":"3","author":"RM McEwen-Smith","year":"2015","unstructured":"McEwen-Smith, R. M., Salio, M. & Cerundolo, V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol. Res. 3, 425\u2013435 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"1061_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng, Q. et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat. Commun. 11, 4835 (2020).","journal-title":"Nat. Commun."},{"key":"1061_CR116","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1164\/rccm.201111-2075OC","volume":"185","author":"MA Sze","year":"2012","unstructured":"Sze, M. A. et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 185, 1073\u20131080 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1061_CR117","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.lungcan.2019.08.022","volume":"136","author":"J Jin","year":"2019","unstructured":"Jin, J. et al. Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: a multiple comparative study design with independent validation. Lung Cancer 136, 129\u2013135 (2019).","journal-title":"Lung Cancer"},{"key":"1061_CR118","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/cells12242801","volume":"12","author":"VGP Souza","year":"2023","unstructured":"Souza, V. G. P. et al. The complex role of the microbiome in non-small cell lung cancer development and progression. Cells 12, 2801 (2023).","journal-title":"Cells"},{"key":"1061_CR119","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1158\/1055-9965.EPI-10-1166","volume":"20","author":"MS Shiels","year":"2011","unstructured":"Shiels, M. S. et al. Increased risk of lung cancer in men with tuberculosis in the \u03b1-tocopherol, \u03b2-carotene cancer prevention study. Cancer Epidemiol. Biomark. Prev. 20, 672\u2013678 (2011).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1061_CR120","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12931-020-01392-2","volume":"21","author":"R Bingula","year":"2020","unstructured":"Bingula, R. et al. Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial. Respir. Res. 21, 129 (2020).","journal-title":"Respir. Res."},{"key":"1061_CR121","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41577-023-00836-2","volume":"23","author":"AL Correia","year":"2023","unstructured":"Correia, A. L. Locally sourced: site-specific immune barriers to metastasis. Nat. Rev. Immunol. 23, 522\u2013538 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1061_CR122","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152\u2013164 (2021).","journal-title":"Nat. Med."},{"key":"1061_CR123","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","volume":"7","author":"L Landi","year":"2019","unstructured":"Landi, L. et al. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J. Immunother. Cancer 7, 316 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR124","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","volume":"13","author":"SN Gettinger","year":"2018","unstructured":"Gettinger, S. N. et al. Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 13, 831\u2013839 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007218","volume":"11","author":"JY Deng","year":"2023","unstructured":"Deng, J. Y. et al. Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer. J. Immunother. Cancer 11, e007218 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR126","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature10160","volume":"474","author":"J Fujisaki","year":"2011","unstructured":"Fujisaki, J. et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 474, 216\u2013219 (2011).","journal-title":"Nature"},{"key":"1061_CR127","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2021.06.024","volume":"159","author":"RD Seban","year":"2021","unstructured":"Seban, R. D. et al. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET\/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. Lung Cancer 159, 45\u201355 (2021).","journal-title":"Lung Cancer"},{"key":"1061_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005921","volume":"11","author":"H Kluger","year":"2023","unstructured":"Kluger, H. et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. J. Immunother. Cancer 11, e005921 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR129","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","volume":"32","author":"AJ Schoenfeld","year":"2021","unstructured":"Schoenfeld, A. J. et al. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann. Oncol. 32, 1597\u20131607 (2021).","journal-title":"Ann. Oncol."},{"key":"1061_CR130","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1136","volume":"4","author":"HJ Park","year":"2021","unstructured":"Park, H. J. et al. Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw. Open. 4, e211136 (2021).","journal-title":"JAMA Netw. Open."},{"key":"1061_CR131","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.3390\/ijms22073736","volume":"22","author":"H Arasanz","year":"2021","unstructured":"Arasanz, H. et al. Hyperprogressive disease: main features and key controversies. Int. J. Mol. Sci. 22, 3736 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1061_CR132","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara, R. et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 4, 1543\u20131552 (2018).","journal-title":"JAMA Oncol."},{"key":"1061_CR133","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/annonc\/mdz123","volume":"30","author":"CG Kim","year":"2019","unstructured":"Kim, C. G. et al. Hyperprogressive disease during PD-1\/PD-L1 blockade in patients with non-small-cell lung cancer. Ann. Oncol. 30, 1104\u20131113 (2019).","journal-title":"Ann. Oncol."},{"key":"1061_CR134","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/cncr.31999","volume":"125","author":"Y Kanjanapan","year":"2019","unstructured":"Kanjanapan, Y. et al. Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities. Cancer 125, 1341\u20131349 (2019).","journal-title":"Cancer"},{"key":"1061_CR135","doi-asserted-by":"publisher","first-page":"843707","DOI":"10.3389\/fonc.2022.843707","volume":"12","author":"Z Zhao","year":"2022","unstructured":"Zhao, Z. et al. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: a systematic review and meta-analysis. Front. Oncol. 12, 843707 (2022).","journal-title":"Front. Oncol."},{"key":"1061_CR136","doi-asserted-by":"publisher","first-page":"427","DOI":"10.37349\/etat.2020.00027","volume":"1","author":"M Brambilla","year":"2020","unstructured":"Brambilla, M. et al. Is hyperprogressive disease a specific phenomenom of immunotherapy? Explor. Target. Antitumor Ther. 1, 427\u2013433 (2020).","journal-title":"Explor. Target. Antitumor Ther."},{"key":"1061_CR137","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1093\/oncolo\/oyad043","volume":"28","author":"LX Li","year":"2023","unstructured":"Li, L. X. et al. Low risk of hyperprogression with first-line chemoimmunotherapy for advanced non-small cell lung cancer: pooled analysis of 7 clinical trials. Oncologist 28, e205\u2013e211 (2023).","journal-title":"Oncologist"},{"key":"1061_CR138","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger, M. et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 21, e18\u2013e28 (2020).","journal-title":"Lancet Oncol."},{"key":"1061_CR139","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"WSME Theelen","year":"2021","unstructured":"Theelen, W. S. M. E. et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir. Med. 9, 467\u2013475 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1061_CR140","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal. Transduct. Target. Ther. 7, 258 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1061_CR141","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925\u2013931 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR142","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai, C. J. et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 403, 171\u2013182 (2024).","journal-title":"Lancet"},{"key":"1061_CR143","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","volume":"42","author":"P Iyengar","year":"2024","unstructured":"Iyengar, P. et al. Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC) [abstract NRG-LU002]. J. Clin. Oncol. 42, 8506 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR144","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"key":"1061_CR145","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1148\/radiol.2020200443","volume":"297","author":"HJ Park","year":"2020","unstructured":"Park, H. J. et al. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology 297, 87\u201396 (2020).","journal-title":"Radiology"},{"key":"1061_CR146","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","volume":"42","author":"LG Paz-Ares","year":"2024","unstructured":"Paz-Ares, L. G. et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J. Clin. Oncol. 42, 2860\u20132872 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00243-7","volume":"6","author":"F Zhang","year":"2022","unstructured":"Zhang, F. et al. Co-occurring genomic alterations and immunotherapy efficacy in NSCLC. NPJ Precis. Oncol. 6, 4 (2022).","journal-title":"NPJ Precis. Oncol."},{"key":"1061_CR148","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","volume":"470","author":"C Liu","year":"2020","unstructured":"Liu, C. et al. The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 470, 95\u2013105 (2020).","journal-title":"Cancer Lett."},{"key":"1061_CR149","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.annonc.2022.07.005","volume":"33","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann. Oncol. 33, 1029\u20131040 (2022).","journal-title":"Ann. Oncol."},{"key":"1061_CR150","doi-asserted-by":"publisher","first-page":"889826","DOI":"10.3389\/fonc.2022.889826","volume":"12","author":"G Ndembe","year":"2022","unstructured":"Ndembe, G. et al. LKB1: can we target an hidden target? Focus on NSCLC. Front. Oncol. 12, 889826 (2022).","journal-title":"Front. Oncol."},{"key":"1061_CR151","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1158\/1078-0432.CCR-20-1985","volume":"27","author":"A Singh","year":"2021","unstructured":"Singh, A. et al. NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes. Clin. Cancer Res. 27, 877\u2013888 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1061_CR152","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000706","volume":"5","author":"S Papillon-Cavanagh","year":"2020","unstructured":"Papillon-Cavanagh, S. et al. STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open. 5, e000706 (2020).","journal-title":"ESMO Open."},{"key":"1061_CR153","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.annonc.2023.01.011","volume":"34","author":"TSK Mok","year":"2023","unstructured":"Mok, T. S. K. et al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann. Oncol. 34, 377\u2013388 (2023).","journal-title":"Ann. Oncol."},{"key":"1061_CR154","first-page":"100431","volume":"4","author":"MC Garassino","year":"2023","unstructured":"Garassino, M. C. et al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic NSCLC. JTO Clin. Res. Rep. 4, 100431 (2023).","journal-title":"JTO Clin. Res. Rep."},{"key":"1061_CR155","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","volume":"9","author":"S Kitajima","year":"2019","unstructured":"Kitajima, S. et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 9, 34\u201345 (2019).","journal-title":"Cancer Discov."},{"key":"1061_CR156","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama, S. et al. STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 76, 999\u20131008 (2016).","journal-title":"Cancer Res."},{"key":"1061_CR157","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s43018-021-00208-6","volume":"2","author":"J Deng","year":"2021","unstructured":"Deng, J. et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nat. Cancer 2, 503\u2013514 (2021).","journal-title":"Nat. Cancer"},{"key":"1061_CR158","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221449","volume":"219","author":"R Ferrara","year":"2022","unstructured":"Ferrara, R. & Roz, L. Eating away T cell responses in lung cancer. J. Exp. Med. 219, e20221449 (2022).","journal-title":"J. Exp. Med."},{"key":"1061_CR159","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"Cancer Genome Atlas Research Network","year":"2012","unstructured":"Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519\u2013525 (2012).","journal-title":"Nature"},{"key":"1061_CR160","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","volume":"22","author":"N Rekhtman","year":"2016","unstructured":"Rekhtman, N. et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin. Cancer Res. 22, 3618\u20133629 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1061_CR161","doi-asserted-by":"publisher","first-page":"S1375","DOI":"10.1016\/j.annonc.2021.10.020","volume":"32","author":"SS Ramalingam","year":"2021","unstructured":"Ramalingam, S. S. et al. Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: efficacy by KRAS, STK11, and KEAP1 mutation status [abstract 4O]. Ann. Oncol. 32, S1375\u2013S1376 (2021).","journal-title":"Ann. Oncol."},{"key":"1061_CR162","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","volume":"18","author":"LG Paz-Ares","year":"2023","unstructured":"Paz-Ares, L. G. et al. First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations. J. Thorac. Oncol. 18, 204\u2013222 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR163","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.jtho.2022.07.073","volume":"17","author":"S Peters","year":"2022","unstructured":"Peters, S. et al. Association between KRAS\/STK11\/KEAP1 mutations and outcomes in POSEIDON: durvalumab \u00b1 tremelimumab + chemotherapy in mNSCLC [abstract OA15.04]. J. Thorac. Oncol. 17, S39\u2013S41 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR164","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.jtho.2021.03.024","volume":"16","author":"JV Alessi","year":"2021","unstructured":"Alessi, J. V. et al. SMARCA4 and other SWItch\/sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition. J. Thorac. Oncol. 16, 1176\u20131187 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR165","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"1061_CR166","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7, 264\u2013276 (2017).","journal-title":"Cancer Discov."},{"key":"1061_CR167","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","volume":"11","author":"M Montesion","year":"2021","unstructured":"Montesion, M. et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 11, 282\u2013292 (2021).","journal-title":"Cancer Discov."},{"key":"1061_CR168","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.annonc.2020.04.004","volume":"31","author":"JH Shim","year":"2020","unstructured":"Shim, J. H. et al. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Ann. Oncol. 31, 902\u2013911 (2020).","journal-title":"Ann. Oncol."},{"key":"1061_CR169","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","volume":"25","author":"D Chowell","year":"2019","unstructured":"Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat. Med. 25, 1715\u20131720 (2019).","journal-title":"Nat. Med."},{"key":"1061_CR170","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","volume":"35","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann. Oncol. 35, 508\u2013522 (2024).","journal-title":"Ann. Oncol."},{"key":"1061_CR171","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"1061_CR172","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"1061_CR173","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 8, 1160\u20131168 (2022).","journal-title":"JAMA Oncol."},{"key":"1061_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1\u201310 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR175","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR176","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","volume":"53","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat. Genet. 53, 11\u201315 (2021).","journal-title":"Nat. Genet."},{"key":"1061_CR177","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jtho.2019.07.006","volume":"14","author":"D Kazdal","year":"2019","unstructured":"Kazdal, D. et al. Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts. J. Thorac. Oncol. 14, 1935\u20131947 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR178","first-page":"PO.19.00171","volume":"3","author":"NI Vokes","year":"2019","unstructured":"Vokes, N. I. et al. Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer. JCO Precis. Oncol. 3, PO.19.00171 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"1061_CR179","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17\u201335 (2020).","journal-title":"Immunity"},{"key":"1061_CR180","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1200\/JCO.21.02010","volume":"40","author":"S Park","year":"2022","unstructured":"Park, S. et al. Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer. J. Clin. Oncol. 40, 1916\u20131928 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14273-0","volume":"11","author":"A Reuben","year":"2020","unstructured":"Reuben, A. et al. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat. Commun. 11, 603 (2020).","journal-title":"Nat. Commun."},{"key":"1061_CR182","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2159-8290.CD-20-0962","volume":"11","author":"MF Sanmamed","year":"2021","unstructured":"Sanmamed, M. F. et al. A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. Cancer Discov. 11, 1700\u20131715 (2021).","journal-title":"Cancer Discov."},{"key":"1061_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501 (2016).","journal-title":"Nat. Commun."},{"key":"1061_CR184","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"1061_CR185","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ccell.2018.05.009","volume":"33","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi, R. et al. Non-conventional inhibitory CD4+Foxp3\u2212PD-1hi T cells as a biomarker of immune checkpoint blockade activity. Cancer Cell 33, 1017\u20131032 e7 (2018).","journal-title":"Cancer Cell"},{"key":"1061_CR186","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1158\/2326-6066.CIR-17-0075","volume":"5","author":"TC Bruno","year":"2017","unstructured":"Bruno, T. C. et al. Antigen-presenting intratumoral B cells affect CD4+ TIL phenotypes in non-small cell lung cancer patients. Cancer Immunol. Res. 5, 898\u2013907 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"1061_CR187","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001054","volume":"8","author":"J Russick","year":"2020","unstructured":"Russick, J. et al. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. J. Immunother. Cancer 8, e001054 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR188","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003890","volume":"10","author":"M Larroquette","year":"2022","unstructured":"Larroquette, M. et al. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1\/PD-L1 antibodies. J. Immunother. Cancer 10, e003890 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR189","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo, G. et al. Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin. Cancer Res. 25, 989\u2013999 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1061_CR190","doi-asserted-by":"publisher","first-page":"eaal3604","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas, S. P. et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. 9, eaal3604 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1061_CR191","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jtho.2022.04.009","volume":"17","author":"M Moutafi","year":"2022","unstructured":"Moutafi, M. et al. Discovery of biomarkers of resistance to immune checkpoint blockade in NSCLC using high-plex digital spatial profiling. J. Thorac. Oncol. 17, 991\u20131001 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14381","volume":"8","author":"J Kargl","year":"2017","unstructured":"Kargl, J. et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat. Commun. 8, 14381 (2017).","journal-title":"Nat. Commun."},{"key":"1061_CR193","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","volume":"12","author":"JA Grout","year":"2022","unstructured":"Grout, J. A. et al. Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors. Cancer Discov. 12, 2606\u20132625 (2022).","journal-title":"Cancer Discov."},{"key":"1061_CR194","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001504","volume":"9","author":"B Ricciuti","year":"2021","unstructured":"Ricciuti, B. et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J. Immunother. Cancer 9, e001504 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR195","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1200\/PO.21.00057","volume":"5","author":"W Zou","year":"2021","unstructured":"Zou, W. et al. ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy. JCO Precis. Oncol. 5, 827\u2013838 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"1061_CR196","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","volume":"28","author":"ES Kim","year":"2022","unstructured":"Kim, E. S. et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat. Med. 28, 939\u2013945 (2022).","journal-title":"Nat. Med."},{"key":"1061_CR197","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","volume":"29","author":"ZJF Assaf","year":"2023","unstructured":"Assaf, Z. J. F. et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat. Med. 29, 859\u2013868 (2023).","journal-title":"Nat. Med."},{"key":"1061_CR198","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/oncolo\/oyab064","volume":"27","author":"EG Sturgill","year":"2022","unstructured":"Sturgill, E. G. et al. Discordance in tumor mutation burden from blood and tissue affects association with response to immune checkpoint inhibition in real-world settings. Oncologist 27, 175\u2013182 (2022).","journal-title":"Oncologist"},{"key":"1061_CR199","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","volume":"28","author":"S Peters","year":"2022","unstructured":"Peters, S. et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat. Med. 28, 1831\u20131839 (2022).","journal-title":"Nat. Med."},{"key":"1061_CR200","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s40425-019-0649-2","volume":"7","author":"M Tamminga","year":"2019","unstructured":"Tamminga, M. et al. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. J. Immunother. Cancer 7, 173 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR201","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2019.05.003","volume":"178","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Lactate is a natural suppressor of RLR signaling by targeting MAVS. Cell 178, 176\u2013189 e15 (2019).","journal-title":"Cell"},{"key":"1061_CR202","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejca.2022.11.032","volume":"181","author":"TBS Miholjcic","year":"2023","unstructured":"Miholjcic, T. B. S. et al. Rationale for LDH-targeted cancer immunotherapy. Eur. J. Cancer 181, 166\u2013178 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1061_CR203","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/cancers11020262","volume":"11","author":"V Hofman","year":"2019","unstructured":"Hofman, V. et al. Circulating tumor cell detection in lung cancer: but to what end? Cancers 11, 262 (2019).","journal-title":"Cancers"},{"key":"1061_CR204","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","volume":"19","author":"G Claps","year":"2022","unstructured":"Claps, G. et al. The multiple roles of LDH in cancer. Nat. Rev. Clin. Oncol. 19, 749\u2013762 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1061_CR205","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nri855","volume":"2","author":"C Thery","year":"2002","unstructured":"Thery, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569\u2013579 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"1061_CR206","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13046-021-02040-3","volume":"40","author":"F Pontis","year":"2021","unstructured":"Pontis, F. et al. Circulating extracellular vesicles from individuals at high-risk of lung cancer induce pro-tumorigenic conversion of stromal cells through transfer of miR-126 and miR-320. J. Exp. Clin. Cancer Res. 40, 237 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1061_CR207","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000376","volume":"8","author":"XX Peng","year":"2020","unstructured":"Peng, X. X. et al. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR\/ALK wild-type advanced non-small cell lung cancer. J. Immunother. Cancer 8, e000376 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR208","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nri2959","volume":"11","author":"AN Akbar","year":"2011","unstructured":"Akbar, A. N. & Henson, S. M. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat. Rev. Immunol. 11, 289\u2013295 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"1061_CR209","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1078-0432.CCR-20-1420","volume":"27","author":"R Ferrara","year":"2021","unstructured":"Ferrara, R. et al. Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent PD-1\/PD-L1 inhibitors or platinum-based chemotherapy. Clin. Cancer Res. 27, 492\u2013503 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1061_CR210","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00262-021-03018-y","volume":"71","author":"DH Kang","year":"2022","unstructured":"Kang, D. H. et al. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1\/PD-L1 inhibitors. Cancer Immunol. Immunother. 71, 579\u2013588 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"1061_CR211","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30863-x","volume":"13","author":"AJ Patel","year":"2022","unstructured":"Patel, A. J. et al. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nat. Commun. 13, 3148 (2022).","journal-title":"Nat. Commun."},{"key":"1061_CR212","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1527498","volume":"8","author":"E Picard","year":"2019","unstructured":"Picard, E. et al. Circulating NKp46+ natural killer cells have a potential regulatory property and predict distinct survival in non-small cell lung cancer. Oncoimmunology 8, e1527498 (2019).","journal-title":"Oncoimmunology"},{"key":"1061_CR213","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita, L. et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 4, 351\u2013357 (2018).","journal-title":"JAMA Oncol."},{"key":"1061_CR214","doi-asserted-by":"publisher","first-page":"100078","DOI":"10.1016\/j.esmoop.2021.100078","volume":"6","author":"GL Banna","year":"2021","unstructured":"Banna, G. L. et al. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 \u226550% advanced non-small-cell lung cancer. ESMO Open. 6, 100078 (2021).","journal-title":"ESMO Open."},{"key":"1061_CR215","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41435-023-00236-5","volume":"25","author":"F Wei","year":"2024","unstructured":"Wei, F. & Sasada, T. Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer. Genes. Immun. 25, 89\u201391 (2024).","journal-title":"Genes. Immun."},{"key":"1061_CR216","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006788","volume":"11","author":"F Wei","year":"2023","unstructured":"Wei, F. et al. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures. J. Immunother. Cancer 11, e006788 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR217","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/1078-0432.CCR-19-2337","volume":"26","author":"D Enrico","year":"2020","unstructured":"Enrico, D. et al. Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation? Clin. Cancer Res. 26, 787\u2013792 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1061_CR218","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1200\/JCO.23.02339","volume":"42","author":"BS Henick","year":"2024","unstructured":"Henick, B. S. et al. Controlled chaos: parsing acquired immunoresistance in lung cancer. J. Clin. Oncol. 42, 1211\u20131214 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR219","doi-asserted-by":"publisher","first-page":"S1242","DOI":"10.1016\/j.annonc.2024.08.2293","volume":"35","author":"P Tomasini","year":"2024","unstructured":"Tomasini, P. et al. Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): a phase Ib\/IIa clinical trial targeting identified resistance pathways [astract LBA8]. Ann. Oncol. 35, S1242 (2024).","journal-title":"Ann. Oncol."},{"key":"1061_CR220","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432526","volume":"44","author":"G Mountzios","year":"2024","unstructured":"Mountzios, G. et al. Beyond chemoimmunotherapy in advanced non-small cell lung cancer: new frontiers, new challenges. Am. Soc. Clin. Oncol. Educ. Book. 44, e432526 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"1061_CR221","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.21037\/tlcr-21-1018","volume":"11","author":"C Grohe","year":"2022","unstructured":"Grohe, C. et al. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: cohort C of the non-interventional study, VARGADO. Transl. Lung Cancer Res. 11, 2010\u20132021 (2022).","journal-title":"Transl. Lung Cancer Res."},{"key":"1061_CR222","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","volume":"13","author":"SE Park","year":"2018","unstructured":"Park, S. E. et al. Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non\u2013small cell lung cancer. J. Thorac. Oncol. 13, 106\u2013111 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR223","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","volume":"112","author":"G Schvartsman","year":"2017","unstructured":"Schvartsman, G. et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112, 90\u201395 (2017).","journal-title":"Lung Cancer"},{"key":"1061_CR224","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004424","volume":"10","author":"C Aggarwal","year":"2022","unstructured":"Aggarwal, C. et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial. J. Immunother. Cancer 10, e004424 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR225","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.21.01845","volume":"40","author":"A Passaro","year":"2022","unstructured":"Passaro, A. et al. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J. Clin. Oncol. 40, 598\u2013610 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR226","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.ctrv.2023.102614","volume":"120","author":"M Borgeaud","year":"2023","unstructured":"Borgeaud, M. et al. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat. Rev. 120, 102614 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"1061_CR227","first-page":"100593","volume":"20","author":"N Peled","year":"2023","unstructured":"Peled, N. et al. MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with\/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy [abstract 121P]. IOTECH 20, 100593 (2023).","journal-title":"IOTECH"},{"key":"1061_CR228","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jtho.2020.10.001","volume":"16","author":"D Spigel","year":"2021","unstructured":"Spigel, D. et al. Randomized phase 2 studies of checkpoint inhibitors alone or in combination with pegilodecakin in patients with metastatic NSCLC (CYPRESS 1 and CYPRESS 2). J. Thorac. Oncol. 16, 327\u2013333 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR229","first-page":"100537","volume":"20","author":"N Leighl","year":"2023","unstructured":"Leighl, N. et al. Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy [abstract 65O]. IOTECH 20, 100537 (2023).","journal-title":"IOTECH"},{"key":"1061_CR230","doi-asserted-by":"publisher","first-page":"107451","DOI":"10.1016\/j.lungcan.2023.107451","volume":"189","author":"L Paz-Ares","year":"2024","unstructured":"Paz-Ares, L. et al. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): a multicenter, randomized, double-blind, phase 3 trial. Lung Cancer 189, 107451 (2024).","journal-title":"Lung Cancer"},{"key":"1061_CR231","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/oncolo\/oyac253","volume":"28","author":"F Barlesi","year":"2023","unstructured":"Barlesi, F. et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with non-small cell lung cancer resistant or refractory to immune checkpoint inhibitors. Oncologist 28, 258\u2013267 (2023).","journal-title":"Oncologist"},{"key":"1061_CR232","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein, C. et al. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug. Discov. 23, 301\u2013319 (2024).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1061_CR233","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp, K. L. et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy \u2014 Lung MAP S1800A. J. Clin. Oncol. 40, 2295\u20132306 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR234","doi-asserted-by":"publisher","first-page":"TPS8657","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8657","volume":"42","author":"KL Reckamp","year":"2024","unstructured":"Reckamp, K. L. et al. SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer [abstract]. J. Clin. Oncol. 42, TPS8657 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR235","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","volume":"35","author":"H Borghaei","year":"2024","unstructured":"Borghaei, H. et al. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Ann. Oncol. 35, 66\u201376 (2024).","journal-title":"Ann. Oncol."},{"key":"1061_CR236","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1200\/JCO.23.02166","volume":"42","author":"J Neal","year":"2024","unstructured":"Neal, J. et al. CONTACT-01: a randomized phase III trial of atezolizumab + cabozantinib versus docetaxel for metastatic non-small cell lung cancer after a checkpoint inhibitor and chemotherapy. J. Clin. Oncol. 42, 2393\u20132403 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR237","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong, A. et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet 405, 839\u2013849 (2025).","journal-title":"Lancet"},{"key":"1061_CR238","doi-asserted-by":"publisher","first-page":"111722","DOI":"10.1016\/j.isci.2024.111722","volume":"28","author":"T Zhong","year":"2025","unstructured":"Zhong, T. et al. Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects. iScience 28, 111722 (2025).","journal-title":"iScience"},{"key":"1061_CR239","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jtho.2023.12.023","volume":"19","author":"JC Yang","year":"2023","unstructured":"Yang, J. C. et al. Pembrolizumab with or without lenvatinib for first-line metastatic non\u2012small-cell lung cancer with PD-L1 tumor proportion score \u22651% (LEAP-007): a randomized, double-blind, phase 3 trial. J. Thorac. Oncol. 19, 941\u2013953 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR240","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau, C. H., Steeg, P. S. & Figg, W. D. Antibody-drug conjugates for cancer. Lancet 394, 793\u2013804 (2019).","journal-title":"Lancet"},{"key":"1061_CR241","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher, A. H. & Brown, M. P. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br. J. Cancer 117, 1736\u20131742 (2017).","journal-title":"Br. J. Cancer"},{"key":"1061_CR242","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.23.00013","volume":"41","author":"A Passaro","year":"2023","unstructured":"Passaro, A., Janne, P. A. & Peters, S. Antibody-drug conjugates in lung cancer: recent advances and implementing strategies. J. Clin. Oncol. 41, 3747\u20133761 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR243","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"MJ Ahn","year":"2025","unstructured":"Ahn, M. J. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J. Clin. Oncol. 43, 260\u2013272 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR244","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jtho.2024.09.050","volume":"19","author":"B Besse","year":"2024","unstructured":"Besse, B. et al. Tusamitamab ravtansine vs docetaxel in previously treated advanced nonsquamous NSCLC: results from phase 3 CARMEN-LC03 trial [abstract OA08.05]. J. Thorac. Oncol. 19, S25\u2013S26 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR245","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","volume":"19","author":"MC Garassino","year":"2024","unstructured":"Garassino, M. C. et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-lung 01 [abstract PL02.11]. J. Thorac. Oncol. 19, S2\u2013S3 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR246","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1200\/JCO.2025.43.16_suppl.8501","volume":"43","author":"BP Levy","year":"2025","unstructured":"Levy, B. P. et al. TROPION-Lung02: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC) [abstract]. J. Clin. Oncol. 43, 8501 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR247","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085680","volume":"389","author":"W Fang","year":"2025","unstructured":"Fang, W. et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. BMJ 389, e085680 (2025).","journal-title":"BMJ"},{"key":"1061_CR248","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","volume":"9","author":"J Fuentes-Antras","year":"2023","unstructured":"Fuentes-Antras, J. et al. Antibody-drug conjugates: in search of partners of choice. Trends Cancer 9, 339\u2013354 (2023).","journal-title":"Trends Cancer"},{"key":"1061_CR249","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1200\/JCO.2024.42.16_suppl.8502","volume":"42","author":"W Fang","year":"2024","unstructured":"Fang, W. et al. Sacituzumab tirumotecan (SKB264\/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study [abstract]. J. Clin. Oncol. 42, 8502 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR250","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K. et al. Exploring the next generation of antibody-drug conjugates. Nat. Rev. Clin. Oncol. 21, 203\u2013223 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1061_CR251","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jtho.2024.03.002","volume":"19","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti, B. & Garassino, M. C. Precision immunotherapy for STK11\/KEAP1-mutant NSCLC. J. Thorac. Oncol. 19, 877\u2013882 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR252","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1158\/1538-7445.AM2024-3916","volume":"84","author":"A Patel","year":"2024","unstructured":"Patel, A. et al. TNG260, a small molecule CoREST inhibitor, sensitizes STK11-mutant NSCLC to anti-PD1 immunotherapy [abstract 3916]. Cancer Res. 84, 3916 (2024).","journal-title":"Cancer Res."},{"key":"1061_CR253","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33430-6","volume":"13","author":"C Kofink","year":"2022","unstructured":"Kofink, C. et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nat. Commun. 13, 5969 (2022).","journal-title":"Nat. Commun."},{"key":"1061_CR254","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34562-5","volume":"13","author":"J Cantley","year":"2022","unstructured":"Cantley, J. et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nat. Commun. 13, 6814 (2022).","journal-title":"Nat. Commun."},{"key":"1061_CR255","doi-asserted-by":"publisher","first-page":"TPS8655","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8655","volume":"42","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis, F. et al. TRITON: phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and\/or KEAP1 and\/or KRAS mutations [abstract]. J. Clin. Oncol. 42, TPS8655 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR256","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse, B. et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat. Med. 30, 716\u2013729 (2024).","journal-title":"Nat. Med."},{"key":"1061_CR257","doi-asserted-by":"publisher","first-page":"TPS9161","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9161","volume":"41","author":"B Besse","year":"2023","unstructured":"Besse, B. et al. LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy [abstract]. J. Clin. Oncol. 41, TPS9161 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR258","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","volume":"10","author":"M Herrera","year":"2024","unstructured":"Herrera, M. et al. Bispecific antibodies: advancing precision oncology. Trends Cancer 10, 893\u2013919 (2024).","journal-title":"Trends Cancer"},{"key":"1061_CR259","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn, M. J. et al. Tarlatamab for patients with previously treated small-cell lung cancer. N. Engl. J. Med. 389, 2063\u20132075 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR260","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1200\/JCO.2023.41.16_suppl.8502","volume":"41","author":"M Wermke","year":"2023","unstructured":"Wermke, M. et al. First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)\/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) [abstract]. J. Clin. Oncol. 41, 8502 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR261","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1200\/JCO.2024.42.16_suppl.8090","volume":"42","author":"H Beltran","year":"2024","unstructured":"Beltran, H. et al. Updated results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC) [abstract]. J. Clin. Oncol. 42, 8090 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR262","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099","author":"G Mountzios","year":"2025","unstructured":"Mountzios, G. et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. New Engl. J. Med., https:\/\/doi.org\/10.1056\/NEJMoa2502099 (2025).","journal-title":"New Engl. J. Med."},{"key":"1061_CR263","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","volume":"24","author":"A Fenis","year":"2024","unstructured":"Fenis, A. et al. New immune cell engagers for cancer immunotherapy. Nat. Rev. Immunol. 24, 471\u2013486 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1061_CR264","doi-asserted-by":"publisher","first-page":"1483884","DOI":"10.3389\/fonc.2024.1483884","volume":"14","author":"SK Nikkhoi","year":"2024","unstructured":"Nikkhoi, S. K., Li, G. & Hatefi, A. Natural killer cell engagers for cancer immunotherapy. Front. Oncol. 14, 1483884 (2024).","journal-title":"Front. Oncol."},{"key":"1061_CR265","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR266","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan, B. C. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat. Med. 27, 1410\u20131418 (2021).","journal-title":"Nat. Med."},{"key":"1061_CR267","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","volume":"14","author":"AJ Schoenfeld","year":"2024","unstructured":"Schoenfeld, A. J. et al. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov. 14, 1389\u20131402 (2024).","journal-title":"Cancer Discov."},{"key":"1061_CR268","doi-asserted-by":"publisher","first-page":"114224","DOI":"10.1016\/j.ejca.2024.114224","volume":"209","author":"P Ma","year":"2024","unstructured":"Ma, P. et al. Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: a review. Eur. J. Cancer 209, 114224 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1061_CR269","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","volume":"29","author":"R Hassan","year":"2023","unstructured":"Hassan, R. et al. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results. Nat. Med. 29, 2099\u20132109 (2023).","journal-title":"Nat. Med."},{"key":"1061_CR270","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008668","volume":"12","author":"M Wermke","year":"2024","unstructured":"Wermke, M. et al. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J. Immunother. Cancer 12, e008668 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1061_CR271","doi-asserted-by":"publisher","first-page":"TPS2678","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2678","volume":"43","author":"SK Basu","year":"2025","unstructured":"Basu, S. K. et al. A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8\u03b1\/\u03b2 coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors [abstract]. J. Clin. Oncol. 43, TPS2678 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR272","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-15-0860","volume":"21","author":"TM Schmitt","year":"2015","unstructured":"Schmitt, T. M. et al. New strategies in engineering T-cell receptor gene-modified T cells to more effectively target malignancies. Clin. Cancer Res. 21, 5191\u20135197 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1061_CR273","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1061_CR274","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat. Med. 30, 2224\u20132234 (2024).","journal-title":"Nat. Med."},{"key":"1061_CR275","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1061_CR276","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal. Transduct. Target. Ther. 8, 450 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1061_CR277","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","volume":"17","author":"JF Vansteenkiste","year":"2016","unstructured":"Vansteenkiste, J. F. et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 17, 822\u2013835 (2016).","journal-title":"Lancet Oncol."},{"key":"1061_CR278","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00432-011-1003-3","volume":"137","author":"C Butts","year":"2011","unstructured":"Butts, C. et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J. Cancer Res. Clin. Oncol. 137, 1337\u20131342 (2011).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1061_CR279","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ejca.2015.07.035","volume":"51","author":"G Giaccone","year":"2015","unstructured":"Giaccone, G. et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur. J. Cancer 51, 2321\u20132329 (2015).","journal-title":"Eur. J. Cancer"},{"key":"1061_CR280","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12094-024-03678-z","volume":"27","author":"X Wang","year":"2024","unstructured":"Wang, X., Niu, Y. & Bian, F. The progress of tumor vaccines clinical trials in non-small cell lung cancer. Clin. Transl. Oncol, 27, 1062\u20131074 (2024).","journal-title":"Clin. Transl. Oncol,"},{"key":"1061_CR281","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","volume":"34","author":"B Besse","year":"2023","unstructured":"Besse, B. et al. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann. Oncol. 34, 920\u2013933 (2023).","journal-title":"Ann. Oncol."},{"key":"1061_CR282","doi-asserted-by":"publisher","first-page":"S874","DOI":"10.1016\/j.annonc.2024.08.1452","volume":"35","author":"SV Liu","year":"2024","unstructured":"Liu, S. V. et al. Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy [abstract 1397TiP]. Ann. Oncol. 35, S874\u2013S875 (2024).","journal-title":"Ann. Oncol."},{"key":"1061_CR283","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"1061_CR284","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"JF Gainor","year":"2024","unstructured":"Gainor, J. F. et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov. 14, 2209\u20132223 (2024).","journal-title":"Cancer Discov."},{"key":"1061_CR285","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","volume":"31","author":"J Lopez","year":"2025","unstructured":"Lopez, J. et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat. Med. 31, 152\u2013164 (2025).","journal-title":"Nat. Med."},{"key":"1061_CR286","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1158\/1078-0432.CCR-23-0422","volume":"29","author":"BA Fox","year":"2023","unstructured":"Fox, B. A. et al. Cancer\u2019s dark matter: lighting the abyss unveils universe of new therapies. Clin. Cancer Res. 29, 2173\u20132175 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1061_CR287","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41587-021-01021-3","volume":"40","author":"T Ouspenskaia","year":"2022","unstructured":"Ouspenskaia, T. et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat. Biotechnol. 40, 209\u2013217 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1061_CR288","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/d41573-023-00118-5","volume":"22","author":"E Dolgin","year":"2023","unstructured":"Dolgin, E. Personalized cancer vaccines pass first major clinical test. Nat. Rev. Drug. Discov. 22, 607\u2013609 (2023).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1061_CR289","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","volume":"18","author":"I Melero","year":"2021","unstructured":"Melero, I. et al. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558\u2013576 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1061_CR290","first-page":"100423","volume":"4","author":"MV Negrao","year":"2023","unstructured":"Negrao, M. V. et al. Vidutolimod in combination with atezolizumab with and without radiation therapy in patients with programmed cell death protein 1 or programmed death-ligand 1 blockade-resistant advanced NSCLC. JTO Clin. Res. Rep. 4, 100423 (2023).","journal-title":"JTO Clin. Res. Rep."},{"key":"1061_CR291","doi-asserted-by":"publisher","first-page":"1479483","DOI":"10.3389\/fimmu.2024.1479483","volume":"15","author":"M Skalickova","year":"2024","unstructured":"Skalickova, M. et al. Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer. Front. Immunol. 15, 1479483 (2024).","journal-title":"Front. Immunol."},{"key":"1061_CR292","doi-asserted-by":"publisher","first-page":"S1183","DOI":"10.1016\/j.annonc.2020.08.2286","volume":"31","author":"F Barlesi","year":"2020","unstructured":"Barlesi, F. et al. Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1\/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study [abstract LBA53]. Ann. Oncol. 31, S1183 (2020).","journal-title":"Ann. Oncol."},{"key":"1061_CR293","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.21.02885","volume":"41","author":"G de Castro Jr.","year":"2023","unstructured":"de Castro, G. Jr. et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u22651% in the KEYNOTE-042 study. J. Clin. Oncol. 41, 1986\u20131991 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1061_CR294","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","volume":"16","author":"J Jassem","year":"2021","unstructured":"Jassem, J. et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC. J. Thorac. Oncol. 16, 1872\u20131882 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR295","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","volume":"18","author":"T Makharadze","year":"2023","unstructured":"Makharadze, T. et al. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 part 2 trial. J. Thorac. Oncol. 18, 755\u2013768 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR296","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski, M. A. et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J. Thorac. Oncol. 16, 1909\u20131924 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1061_CR297","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.lungcan.2017.05.021","volume":"112","author":"LG Paz-Ares","year":"2017","unstructured":"Paz-Ares, L. G. et al. Treatment outcomes by histology in REVEL: a randomized phase III trial of ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer 112, 126\u2013133 (2017).","journal-title":"Lung Cancer"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01061-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01061-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01061-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:03:08Z","timestamp":1760961788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01061-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":297,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01061-7","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"10 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R. has acted as a speaker and\/or consultant for AbbVie, Amgen, AstraZeneca, Beigene, Boehringer-Ingelheim, BMS, Daiichi-Sankyo, Gilead, GSK, Lilly, Merck-Serono, MSD, Novartis, Pfizer, PharmaMar, Pierre-Fabre, Regeneron and Roche. N.F. has acted as a speaker and\/or consultant for AbbVie, Amgen, AstraZeneca, BeiGene, Berlinchemie, Boehringer-Ingelheim, BMS, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda; and has received research funding from Roche. S.P. has acted as a consultant for AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BioNTech, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, Blueprint Medicines, Boehringer-Ingelhim, BMS, Clovis, Daiichi Sankyo, Debiopharm, Lilly, F-Star, Foundation Medicine, Genmab, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Qlucore, Merck, Novocure, PharmaMar, Promontory Therapeutics, Pfizer, Regeneron, Roche\/Genentech, Sanofi, Seattle Genetics, Takeda and Zymeworks; has acted as a speaker for AstraZeneca, Boehringer-Ingelheim, BMS, Lilly, Foundation Medicine, GSK, Illumina, Ipsen, MSD, Mirati, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics and Takeda; and has received research funding for trials sponsored by Amgen, Arcus, AstraZeneca, Beigene, BMS, Lilly, GSK, iTeos, Mirati, MSD, PharaMar, Promonotory Therapeutics, Roche and Seattle Genetics. B.A.F. has acted as a consultant and\/or adviser for Calidi, Merck, Pfizer, PrimeVax and Turnstone; has received research funding from BMS, Akkoya Biosciences, Hamamatsu, Incyte, Merck and Shimadzu; and is a founder of, holds stocks in, and has intellectual propertiy licensed to UbiVac. F.B. has acted as a consultant and\/or adviser for Abbvie, ACEA, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Eisai, Lilly, Genentech, Ignyta, Innate Pharma, Ipsen, Loxo, Medimmune, Merck, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi-Aventis, Summit Therapeutics and Takeda; and has non-financial interests in AstraZeneca, BMS, Innate Pharma, Merck, Mirati, Pierre Fabre and Roche. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}